Qingyu Zhou

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. pmc Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts
    Qingyu Zhou
    Department of Pharmacology and Systems Therapeutics, Systems Biology Center New York, Mount Sinai School of Medicine, New York, NY, USA
    J Pharmacol Exp Ther 343:509-19. 2012
  2. pmc Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues
    Hua Lv
    Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Invest New Drugs 30:2263-73. 2012
  3. pmc The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic
    Qingyu Zhou
    Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA
    AAPS J 13:111-20. 2011

Collaborators

Detail Information

Publications3

  1. pmc Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts
    Qingyu Zhou
    Department of Pharmacology and Systems Therapeutics, Systems Biology Center New York, Mount Sinai School of Medicine, New York, NY, USA
    J Pharmacol Exp Ther 343:509-19. 2012
    ....
  2. pmc Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues
    Hua Lv
    Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Invest New Drugs 30:2263-73. 2012
    ....
  3. pmc The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic
    Qingyu Zhou
    Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA
    AAPS J 13:111-20. 2011
    ..Finally, given the innovative techniques to measure tissue drug concentrations and associated biomarkers of drug responses, development of predictive PK/PD models will become a standard approach for drug discovery and development...